Schreiner MediPharm, a Germany-based provider of specialty pharmaceutical labeling solutions for over 65 years,working in conjunction with the Dutch technology companyECCT(Experts in Communications & Connectivity Technology), has developed a smart blister pack for a global pharmaceutical corporation to enhance medication adherence by clinical trial participants.
While clinical trials require high accuracy, reliable workflow, efficiency, speed and flexibility, the conventional, non-automated processes are frequently error-prone. Medication adherence by participating patients is critical for the successful outcome of clinical trials, but often difficult to track. Usually, about 20% of patients do not adhere to medication therapy, forcing trial organizers to compensate for the resulting accuracy deficit by increasing patient populations up to 60%.
To improve medication adherence, Schreiner MediPharm collaborated with ECCT and the pharmaceutical corporation involved to develop a smart packaging solution for patient compliance monitoring.When a patient pushes a tablet from the blister pack, data is generated in real time, which may include medication type, extraction time and specific cavity. The data is automatically stored in the smart packaging and transmitted to a database via smartphone app or reader.
This digital therapy monitoring allows physicians, for example, to verify that patients have taken their medicine at the right time. Additionally, the technology makes interactive communication between physicians and patients possible. For instance, physicians can send compliance reminders or dose adjustments to patients.
The smart packaging solution includes printed electronics without impacting the packaging design, and a smart database platform enables diverse data transfers and analyses. Schreiner MediPharm supplied the printing technology, and ECCT provided the package’s smart sensors.
The benefits of utilizing this digital patient compliance monitoring tool include:
Increased efficiency of the clinical trial process as a result of reduced manual documentation and monitoring
Enhanced data quality and reduced delinquency rate due to non-compliance
Greater flexibility in adjusting complex therapies and trial workflows
Shortening of trial periods and accelerated approval process for new medicines